title: Chronic dosing with mirtazapine does not produce sedation in rats.
abstract: Sedation/somnolence are major side effects of pharmacotherapies for depression, and negatively affect long-term treatment compliance in depressed patients. Use of mirtazapine (MIR), an atypical antidepressant approved for the treatment of moderate to severe depression with comorbid anxiety disorders, is associated with significant sedation/somnolence, especially in short-term therapy. Nonetheless, studies with human subjects suggest that MIR-induced sedation is transient, especially when high and repeated doses are used. The purpose of this study was to explore the effects of acute and chronic administration of different doses of MIR on sedation in the rat.
  Assessment of sedation was carried out behaviorally using the rotarod, spontaneous locomotor activity, and fixed-bar tests.
  A 15-mg/kg dose of MIR induced sedative effects for up to 60 minutes, whereas 30 mg/kg or more produced sedation within minutes and only in the first few days of administration.
  These results suggest that 30 mg/kg is a safe, well-tolerated dose of MIR which generates only temporary sedative effects.
authors.affiliation: Laboratorio de Neurobiología Molecular y Neuroquímica de Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
authors.forename: Alberto
authors.initials: A
authors.lastname: Salazar-Juárez
authors.affiliation: Laboratorio de Neurobiología Molecular y Neuroquímica de Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
authors.forename: Susana
authors.initials: S
authors.lastname: Barbosa-Méndez
authors.affiliation: Laboratorio de Neurobiología Molecular y Neuroquímica de Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
authors.forename: Paola
authors.initials: P
authors.lastname: Merino-Reyes
authors.affiliation: Laboratorio de Neurobiología Molecular y Neuroquímica de Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
authors.forename: Maura
authors.initials: M
authors.lastname: Matus-Ortega
authors.affiliation: Laboratorio de Neurobiología Molecular y Neuroquímica de Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Hernández-Calderón
authors.affiliation: Laboratorio de Neurobiología Molecular y Neuroquímica de Adicciones, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City, Mexico.
authors.forename: Benito
authors.initials: B
authors.lastname: Antón
mesh_terms: D000818:Animals; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006993:Hypnotics and Sedatives / Q000494:pharmacology*; D008124:Locomotion / Q000187:drug effects*; D008297:Male; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000078785:Mirtazapine; D017208:Rats, Wistar; D045442:Rotarod Performance Test / Q000379:methods; D013997:Time Factors; D014196:Trazodone / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000929:Antidepressive Agents, Tricyclic; D006993:Hypnotics and Sedatives; D008803:Mianserin; D000078785:Mirtazapine; D014196:Trazodone